Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Dec;39(12):1147-61.
doi: 10.1007/s11745-004-1342-z.

n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients

Affiliations
Review

n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients

Philip C Calder. Lipids. 2004 Dec.

Abstract

Excessive or inappropriate inflammation and immunosuppression are components of the response to surgery, trauma, injury, and infection in some individuals and these can lead, progressively, to sepsis and septic shock. The hyperinflammation is characterized by the production of inflammatory cytokines, arachidonic acid-derived eicosanoids, and other inflammatory mediators, while the immunosuppression is characterized by impairment of antigen presentation and of T helper cell type-1 responses. Long-chain n-3 FA from fish oil decrease the production of inflammatory cytokines and eicosanoids. They act both directly (by replacing arachidonic acid as an eicosanoid substrate and by inhibiting arachidonic acid metabolism) and indirectly (by altering the expression of inflammatory genes through effects on transcription factor activation). Thus, long-chain n-3 FA are potentially useful anti-inflammatory agents and may be of benefit in patients at risk of developing sepsis. As such, an emerging application of n-3 FA is in surgical or critically ill patients where they may be added to parenteral or enteral formulas. Parenteral or enteral nutrition including n-3 FA appears to preserve immune function better than standard formulas and appears to partly prevent some aspects of the inflammatory response. Studies to date are suggestive of clinical benefits from these approaches, especially in postsurgical patients.

PubMed Disclaimer

References

    1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest. 1997;101:1644–1655. - PubMed
    1. Warren H.S. Strategies for the Treatment of Sepsis. N. Engl. J. Med. 1997;336:952–953. doi: 10.1056/NEJM199703273361311. - DOI - PubMed
    1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of Severe Sepsis in the United States: Analysis of Incidence, Outcome, and Associated Costs of Care. Crit. Care Med. 2001;29:1303–1310. doi: 10.1097/00003246-200107000-00002. - DOI - PubMed
    1. Friedman G., Silva E., Vincent J.-L. Has the Mortality of Septic Shock Changed with Time? Crit. Care Med. 1998;26:2078–2086. doi: 10.1097/00003246-199812000-00045. - DOI - PubMed
    1. Brun-Buisson C. The Epidemiology of the Systemic Inflammatory Response Syndrome. Intensive Care Med. 2000;26:S64–S74. doi: 10.1007/s001340051121. - DOI - PMC - PubMed

MeSH terms